Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2018

Introduction of a Standardised On-treatment Radiation Mucositis Pain Management Protocol in a Head and Neck Cancer Oncology Unit (#208)

Elizabeth Kernutt 1 , Rohen White 1 , Joshua Dass 1 , Colin Tang 1 , Joanna Dewar 2 , Annette Lim 2 3
  1. Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia
  2. Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia
  3. School of Medicine, University of Western Australia, Crawley, WA, Australia


Curative intent radiotherapy (RT), adjuvant or definitive, is required in 70% of Head and Neck Cancer (HNC) diagnoses1. Severe on-treatment toxicities including radiation mucositis are common, especially with concurrent chemotherapy. If not managed effectively, toxicity can lead to malnutrition, morbidity and poorer disease outcomes2. Weight loss (WL) is a surrogate for nutritional status and an independent predictor of overall and disease-specific survival, local tumour control, quality of life and late complications2-8. As such symptom control and nutritional management represents a clinical need to be improved. Several topical and systemic therapies are available to alleviate mucositis-related symptoms but their optimal combination is unknown9-12.


To assess the introduction of a standardised on-treatment radiation mucositis pain management protocol in a HNC Oncology Unit in a large tertiary hospital.


Prospective data was collected pre and post protocol introduction. Primary endpoint was WL from start of RT - 12 weeks following RT. Secondary endpoints were WL from diagnosis, WL during RT, oral mucositis, pain scores, unplanned hospital admissions, enterostomy use and treatment delays. Data was collected throughout treatment, 1 and 3 months post RT.


At preliminary analysis, 74 and 69 patients were enrolled pre and post-protocol, respectively. Groups were not statistically different in demographic, tumour and treatment characteristics. Median percentage WL from start - 12wks post RT improved between groups (12.3% vs. 8.7%) as has median percentage WL on-treatment (9.5% vs. 7.7%). No significant difference in admission rate or median length of stay was noted. Updated results will be presented. 


Introduction of a standardised mucositis symptom control pathway for HNC patients receiving curative intent RT has reduced WL and other markers of patient morbidity. Further analysis will be completed to determine the extent to which the protocol influences outcomes. Quality of life analysis and refinement of analgesia pathways continue.

  1. Barton M. Review of Optimal Radiotherapy Utilisation Rates. 2013.
  2. Capuano G, Grosso A, Gentile PC, Battista M, Bianciardi F, Di Palma A, et al. Influence of weight loss on outcomes in patients with head and neck cancer undergoing concomitant chemoradiotherapy. Head Neck. 2008 Apr;30(4):503-8.
  3. Langius JA, Twisk J, Kampman M, Doornaert P, Kramer MH, Weijs PJ, et al. Prediction model to predict critical weight loss in patients with head and neck cancer during (chemo)radiotherapy. Oral Oncol. 2016 Jan;52:91-6.
  4. Langius JA, Zandbergen MC, Eerenstein SE, van Tulder MW, Leemans CR, Kramer MH, et al. Effect of nutritional interventions on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo)radiotherapy: a systematic review. Clin Nutr. 2013 Oct;32(5):671-8.
  5. Chang PH, Yeh KY, Huang JS, Lai CH, Wu TH, Lan YJ, et al. Pretreatment performance status and nutrition are associated with early mortality of locally advanced head and neck cancer patients undergoing concurrent chemoradiation. Eur Arch Otorhinolaryngol. 2013 May;270(6):1909-15.
  6. Gourin CG, Couch ME, Johnson JT. Effect of weight loss on short-term outcomes and costs of care after head and neck cancer surgery. Ann Otol Rhinol Laryngol. 2014 Feb;123(2):101-10.
  7. Ghadjar P, Hayoz S, Zimmermann F, Bodis S, Kaul D, Badakhshi H, et al. Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94). Radiat Oncol. 2015;10:21.
  8. Head BA, Heitz L, Keeney C, Myers J, Appana SN, Studts JL, et al. The relationship between weight loss and health-related quality of life in persons treated for head and neck cancer. Support Care Cancer. 2011 Oct;19(10):1511
  9. Ling, I.S. and B. Larsson, Individualized pharmacological treatment of oral mucositis pain in patients with head and neck cancer receiving radiotherapy. Support Care Cancer, 2011. 19(9): p. 1343-50.
  10. Cerchietti, L., Morphine mouthwashes for painful mucositis. Support Care Cancer, 2007. 15(1): p. 115-6; author reply 117.
  11. Cerchietti, L.C., et al., Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer, 2002. 95(10): p. 2230-6.
  12. Lalla, R.V., et al., MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014. 120(10): p. 1453-61